Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 2/20 | 0.57 |
| ▸ | PIM1 | P11309 | 2/20 | 0.57 |
| ▸ | BRAF | P15056 | 16/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | NEK2 | P51955 | 1/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.45 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5797477 | 0.93 | BRAF (0.54) | MAPK13PIM1BRAFRAF1MAPK14 | |
| SCHEMBL5798319 | 0.92 | BRAF (0.53) | MAPK13PIM1BRAFRAF1MAPK14 | |
| SCHEMBL5812817 | 0.88 | BRAF (0.55) | MAPK13PIM1BRAFRAF1MAPK14 | |
| SCHEMBL5798368 | 0.88 | BRAF (0.52) | MAPK13PIM1BRAFRAF1MAPK14 | |
| SCHEMBL5808099 | 0.88 | BRAF (0.50) | MAPK13PIM1BRAFFYNRAF1 | |
| SCHEMBL5799997 | 0.88 | BRAF (0.55) | BRAFRAF1MAPK14 | |
| SCHEMBL5807451 | 0.88 | BRAF (0.55) | BRAFFYNRAF1MAPK14 | |
| SCHEMBL5799436 | 0.88 | BRAF (0.59) | BRAFRAF1MAPK14 | |
| SCHEMBL5946534 | 0.87 | BRAF (0.56) | MAPK13PIM1BRAFRAF1MAPK14 | |
| SCHEMBL5813271 | 0.86 | BRAF (0.53) | BRAFRAF1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006033795-A2 | SUBSTITUTED PYRAZOLO [1, 5-A] PYRIMIDINES FOR INHIBITING ABNORMAL CELL GROWTH | WYETH (US) | 2006-03-30 | — | — | WO | claimed |
| WO-2006033796-A1 | SUBSTITUTED PYRAZOLO [1,5-a] PYRIMIDINES AND PROCESS FOR MAKING SAME | WYETH (US) | 2006-03-30 | — | — | WO | claimed |
| US-20060063784-A1 | Method of using substituted pyrazolo [1,5-a] pyrimidines | WYETH | 2006-03-23 | — | — | US | claimed |
| US-20060063785-A1 | Substituted pyrazolo[1,5-a] pyrimidines and process for making same | WYETH | 2006-03-23 | — | — | US | claimed |
| WO-2006033795-A2 | SUBSTITUTED PYRAZOLO [1, 5-A] PYRIMIDINES FOR INHIBITING ABNORMAL CELL GROWTH | WYETH (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006033796-A1 | SUBSTITUTED PYRAZOLO [1,5-a] PYRIMIDINES AND PROCESS FOR MAKING SAME | WYETH (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063784-A1 | Method of using substituted pyrazolo [1,5-a] pyrimidines | WYETH | 2006-03-23 | — | — | US | disclosed |
| US-20060063785-A1 | Substituted pyrazolo[1,5-a] pyrimidines and process for making same | WYETH | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063785-A1 | Substituted pyrazolo[1,5-a] pyrimidines and process for making same | TYMP, DPYD, TYMS | MAPK13 1171/4885PIM1 586/4885BRAF 214/4885 |
| US-20060063784-A1 | Method of using substituted pyrazolo [1,5-a] pyrimidines | TYMP, DPYD, TYMS | MAPK13 1727/4885PIM1 797/4885BRAF 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.